SCHEMBL10200042

SCHEMBL10200042

OC(c1cnc(-c2ccc(C(F)(F)F)cc2)nc1)C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 5/20 0.47
GABBR2 O75899 3/20 0.42
GABBR1 Q9UBS5 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
PAX8 Q06710 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PDE2A O00408 1/20 0.40
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TRPV1 Q8NER1 4/20 0.37
HDAC4 P56524 1/20 0.37
PSEN1 P49768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9951087 0.99 TRPV3 (0.45) TRPV3GABBR2GABBR1MEN1KMT2A
SCHEMBL10199934 0.86 TRPV3 (0.44) TRPV3GABBR2GABBR1MEN1KMT2A
SCHEMBL26081058 0.81 DHODH (0.50) MEN1KMT2AGAAMAPTMAPK1
SCHEMBL7713434 0.76 PDE2A (0.39) GABBR2GABBR1MEN1KMT2APDE2A
SCHEMBL9951059 0.74 MAPT (0.47) MEN1KMT2AMAPTLMNATRPV1
SCHEMBL9951410 0.74 GCGR (0.48) TRPV3TRPV1
SCHEMBL1348888 0.72 PDE2A (0.57) PDE2AIDO1TDO2
SCHEMBL9951577 0.72 GCGR (0.48) TRPV3LMNAHDAC4PSEN1PSEN2
SCHEMBL10200355 0.72 TRPV3 (0.46) TRPV3PDE2ALMNAHDAC4PSEN1
SCHEMBL9951123 0.72 GCGR (0.49) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 US disclosed
US-8933104-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-01-13 US disclosed
US-8933104-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-01-13 US disclosed
US-20140329862-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2014-11-06 US disclosed
US-20140329862-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2014-11-06 US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 US disclosed
US-8809342-B2 Glucagon receptor modulators PFIZER INC. (US) 2014-08-19 US disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329862-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 TRPV3 598/4885GABBR2 785/4885GABBR1 1056/4885
US-20150094338-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 TRPV3 598/4885GABBR2 785/4885GABBR1 1056/4885
US-20120165343-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 TRPV3 598/4885GABBR2 785/4885GABBR1 1056/4885
US-20150266861-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 TRPV3 598/4885GABBR2 785/4885GABBR1 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.